Diabetes Mellitus and Advanced Liver Fibrosis Are Risk Factors for Severe Anemia During Telaprevir-based Triple Therapy

BACKGROUND: Adding telaprevir to pegylated-interferon and ribavirin increased both response rates and side effects of hepatitis C virus (HCV) treatment. AIMS: We identified variables associated with severe anemia during telaprevir-based triple therapy. METHODS: An observational study was performed o...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: Crismale, James F., Martel-Laferrière, Valérie, Bichoupan, Kian, Schonfeld, Emily, Pappas, Alexis, Wyatt, Christina, Odin, Joseph A., Liu, Lawrence U., Schiano, Thomas D., Perumalswami, Ponni V., Bansal, Meena, Dieterich, Douglas T., Branch, Andrea D.
Format: Artigo
Idioma:Inglês
Publicat: 2013
Matèries:
Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC3972374/
https://ncbi.nlm.nih.gov/pubmed/24118693
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/liv.12342
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars